• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血小板与淋巴细胞比值在胰腺癌中的预后作用：一项纳入3028例患者的荟萃分析。

Prognostic role of platelet to lymphocyte ratio in pancreatic cancers: A meta-analysis including 3028 patients.

作者信息

Li Wendi, Tao Lianyuan, Lu Meng, Xiu Dianrong

机构信息

Department of General Surgery, Peking University Third Hospital, Beijing, China.

出版信息

Medicine (Baltimore). 2018 Feb;97(8):e9616. doi: 10.1097/MD.0000000000009616.

DOI:10.1097/MD.0000000000009616
PMID:29465553
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5841988/
Abstract

BACKGROUND

Platelet to lymphocyte ratio (PLR) was recently reported being associated with the prognosis of pancreatic cancer (PC), but the prognostic value of PLR in pancreatic cancer remains inconsistent. We conduct a meta-analysis to evaluate the prognostic role of PLR in patients with PC.

METHODS

PubMed, Embase, Cochrane Library, and Web of Science were systematically searched for eligible studies which investigated the relationship between PLR and clinical outcome of patients with pancreatic cancer. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to evaluate the prognostic role of PLR in overall survival (OS) and progression-free survival (PFS)/time to progression (TTP).

RESULTS

A total of 16 studies comprising 3028 patients with PC were enrolled in this meta-analysis. Pooled analysis demonstrated that elevated PLR predicted a poor OS (HR = 1.22, 95% CI: 1.09-1.36, P < .001). Prognostic role of PLR on OS were significant in subgroup of Asians (HR = 1.22, 95% CI: 1.11-1.34, P < .001), patients treated with chemotherapy (HR = 1.18, 95% CI: 1.04-1.35, P = .01) and mixed methods (HR = 1.29, 95% CI: 1.07-1.57, P = .009), American joint committee on cancer (AJCC) stage of III-IV (HR = 1.22, 95% CI: 1.09-1.36, P < .001), pathological subtype of pancreatic adenocarcinoma (HR = 1.21, 95% CI: 1.08-1.36, P = .001), and cut-off value of PLR ≥160 (HR = 1.48, 95% CI: 1.25-1.75, P < .001).

CONCLUSIONS

An elevated PLR is associated with unfavorable overall survival in patients with pancreatic cancer.

摘要

背景

血小板与淋巴细胞比值（PLR）最近被报道与胰腺癌（PC）的预后相关，但PLR在胰腺癌中的预后价值仍不一致。我们进行了一项荟萃分析，以评估PLR在胰腺癌患者中的预后作用。

方法

系统检索PubMed、Embase、Cochrane图书馆和Web of Science，以查找研究PLR与胰腺癌患者临床结局之间关系的符合条件的研究。计算合并风险比（HR）和95%置信区间（CI），以评估PLR在总生存期（OS）和无进展生存期（PFS）/疾病进展时间（TTP）方面的预后作用。

结果

本荟萃分析共纳入16项研究，包括3028例胰腺癌患者。汇总分析表明，PLR升高预示着较差的总生存期（HR = 1.22，95%CI：1.09 - 1.36，P <.001）。PLR对总生存期的预后作用在亚洲人亚组（HR = 1.22，95%CI：1.11 - 1.34，P <.001）、接受化疗的患者（HR = 1.18，95%CI：1.04 - 1.35，P =.01）和混合方法组（HR = 1.29，95%CI：1.07 - 1.57，P =.009）、美国癌症联合委员会（AJCC）III - IV期（HR = 1.22，95%CI：1.09 - 1.36，P <.001）、胰腺腺癌病理亚型（HR = 1.21，95%CI：1.08 - 1.36，P =.001）以及PLR临界值≥160（HR = 1.48，95%CI：1.25 - 1.75，P <.001）中具有显著性。

结论

PLR升高与胰腺癌患者不良的总生存期相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/48115f17c8c4/medi-97-e9616-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/33d29797926a/medi-97-e9616-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/5658300233ab/medi-97-e9616-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/b82c7303634f/medi-97-e9616-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/788ce3ae8664/medi-97-e9616-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/38e30f1e2be4/medi-97-e9616-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/48115f17c8c4/medi-97-e9616-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/33d29797926a/medi-97-e9616-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/5658300233ab/medi-97-e9616-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/b82c7303634f/medi-97-e9616-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/788ce3ae8664/medi-97-e9616-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/38e30f1e2be4/medi-97-e9616-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/524a/5841988/48115f17c8c4/medi-97-e9616-g008.jpg

相似文献

1
Prognostic role of platelet to lymphocyte ratio in pancreatic cancers: A meta-analysis including 3028 patients.血小板与淋巴细胞比值在胰腺癌中的预后作用：一项纳入3028例患者的荟萃分析。
Medicine (Baltimore). 2018 Feb;97(8):e9616. doi: 10.1097/MD.0000000000009616.
2
Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: A meta-analysis including 3,720 patients.血小板与淋巴细胞比值在非小细胞肺癌中的预后作用：一项纳入3720例患者的荟萃分析。
Int J Cancer. 2016 Jul 1;139(1):164-70. doi: 10.1002/ijc.30060. Epub 2016 Mar 24.
3
Platelet-lymphocyte ratio acts as an independent predictor of prognosis in patients with renal cell carcinoma.血小板-淋巴细胞比值可作为肾细胞癌患者预后的独立预测因子。
Clin Chim Acta. 2018 May;480:166-172. doi: 10.1016/j.cca.2018.02.014. Epub 2018 Feb 17.
4
Preoperative platelet lymphocyte ratio as independent predictors of prognosis in pancreatic cancer: A systematic review and meta-analysis.术前血小板淋巴细胞比值作为胰腺癌预后的独立预测因素：一项系统评价和荟萃分析。
PLoS One. 2017 Jun 2;12(6):e0178762. doi: 10.1371/journal.pone.0178762. eCollection 2017.
5
Preoperative Platelet to Lymphocyte Ratio as a Prognostic Factor for Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis.术前血小板与淋巴细胞比值作为可切除胰腺癌的预后因素：系统评价和荟萃分析。
Dig Surg. 2020;37(6):447-455. doi: 10.1159/000508444. Epub 2020 Jul 20.
6
Prognostic Value of the Platelet-to-Lymphocyte Ratio in Patients With Melanoma: A Meta-Analysis.血小板与淋巴细胞比值在黑色素瘤患者中的预后价值：一项荟萃分析
Front Oncol. 2020 Jul 28;10:1116. doi: 10.3389/fonc.2020.01116. eCollection 2020.
7
Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: A meta-analysis.血小板与淋巴细胞比值对卵巢癌患者预后的意义：一项荟萃分析。
Eur J Clin Invest. 2018 May;48(5):e12917. doi: 10.1111/eci.12917. Epub 2018 Mar 24.
8
Prognostic role of platelet to lymphocyte ratio in esophageal cancer: A meta-analysis.血小板与淋巴细胞比值在食管癌中的预后作用：一项荟萃分析。
Oncotarget. 2017 Nov 20;8(67):112085-112093. doi: 10.18632/oncotarget.22557. eCollection 2017 Dec 19.
9
Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis.血小板-淋巴细胞比值在结直肠癌中的预后作用：一项系统评价和荟萃分析。
Medicine (Baltimore). 2016 Jun;95(24):e3837. doi: 10.1097/MD.0000000000003837.
10
Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients.血小板与淋巴细胞比值在非小细胞肺癌中的预后价值：来自3430例患者的证据
Sci Rep. 2016 Mar 30;6:23893. doi: 10.1038/srep23893.

引用本文的文献

1
Prognostic impact of inflammatory and nutritional biomarkers in pancreatic cancer.炎症和营养生物标志物对胰腺癌的预后影响
World J Clin Oncol. 2025 Jan 24;16(1):101191. doi: 10.5306/wjco.v16.i1.101191.
2
Serum hsa-miR-22-3p, hsa-miR-885-5p, Lipase-to-Amylase Ratio, C-Reactive Protein, CA19-9, and Neutrophil-to-Lymphocyte Ratio as Prognostic Factors in Advanced Pancreatic Ductal Adenocarcinoma.血清hsa-miR-22-3p、hsa-miR-885-5p、脂肪酶与淀粉酶比值、C反应蛋白、CA19-9及中性粒细胞与淋巴细胞比值作为晚期胰腺导管腺癌的预后因素
Curr Issues Mol Biol. 2025 Jan 3;47(1):27. doi: 10.3390/cimb47010027.
3
Glucose-to-Lymphocyte Ratio (GLR) as an Independent Prognostic Factor in Patients with Resected Pancreatic Ductal Adenocarcinoma-Cohort Study.

本文引用的文献

1
Elevated pretreatment neutrophil/white blood cell ratio and monocyte/lymphocyte ratio predict poor survival in patients with curatively resected non-small cell lung cancer: Results from a large cohort.术前中性粒细胞/白细胞比值和单核细胞/淋巴细胞比值升高预示可切除的非小细胞肺癌患者预后不良：来自大样本的结果。
Thorac Cancer. 2017 Jul;8(4):350-358. doi: 10.1111/1759-7714.12454. Epub 2017 May 22.
2
Significance of baseline and change in neutrophil-to-lymphocyte ratio in predicting prognosis: a retrospective analysis in advanced pancreatic ductal adenocarcinoma.中性粒细胞与淋巴细胞比值的基线水平和变化对预测预后的意义：晚期胰腺导管腺癌的回顾性分析。
Sci Rep. 2017 Apr 9;7(1):753. doi: 10.1038/s41598-017-00859-5.
3
葡萄糖与淋巴细胞比值（GLR）作为胰管腺癌切除患者的独立预后因素——队列研究
Cancers (Basel). 2024 May 11;16(10):1844. doi: 10.3390/cancers16101844.
4
The Role of Pretreatment Serum Interleukin 6 in Predicting Short-Term Mortality in Patients with Advanced Pancreatic Cancer.治疗前血清白细胞介素6在预测晚期胰腺癌患者短期死亡率中的作用
Biomedicines. 2024 Apr 18;12(4):903. doi: 10.3390/biomedicines12040903.
5
A Retrospective Study Investigating the Safety and Efficacy of Nanoliposomal Irinotecan in Elderly Patients with Unresectable Pancreatic Cancer.一项关于纳米脂质体伊立替康在不可切除胰腺癌老年患者中的安全性和有效性的回顾性研究。
J Clin Med. 2023 May 15;12(10):3477. doi: 10.3390/jcm12103477.
6
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis.新辅助治疗后接受手术切除的胰腺癌患者的身体成分参数、免疫营养指标及手术结果：一项回顾性多中心分析
Front Nutr. 2023 Feb 13;10:1065294. doi: 10.3389/fnut.2023.1065294. eCollection 2023.
7
A case of improved quality of life in a patient with inoperable pancreatic cancer after repeated RFA.一例无法手术切除的胰腺癌患者经多次射频消融后生活质量改善的病例。
Radiol Case Rep. 2022 Jul 29;17(10):3607-3610. doi: 10.1016/j.radcr.2022.07.017. eCollection 2022 Oct.
8
Prognostic values of platelet-associated indicators in advanced breast cancer.晚期乳腺癌中血小板相关指标的预后价值
Transl Cancer Res. 2019 Aug;8(4):1326-1335. doi: 10.21037/tcr.2019.07.28.
9
Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State.外周血淋巴细胞百分比可预测晚期胰腺癌患者的化疗耐受性和生存情况。适应性免疫与营养状态的关系。
Curr Oncol. 2021 Aug 26;28(5):3280-3296. doi: 10.3390/curroncol28050285.
10
May hemocytometer parameters be a biomarker in distinguishing between adrenal adenomas and carcinomas and in prognosis of adrenocortical carcinomas?血细胞计数器参数可否作为鉴别肾上腺腺瘤和癌以及预测肾上腺皮质癌预后的生物标志物？
Acta Clin Croat. 2020 Sep;59(3):439-444. doi: 10.20471/acc.2020.59.03.07.
Serum lactate dehydrogenase predicts prognosis and correlates with systemic inflammatory response in patients with advanced pancreatic cancer after gemcitabine-based chemotherapy.
血清乳酸脱氢酶预测吉西他滨为基础化疗后晚期胰腺癌患者的预后，并与全身炎症反应相关。
Sci Rep. 2017 Mar 27;7:45194. doi: 10.1038/srep45194.
4
Lymphocyte-to-monocyte ratio can predict mortality in pancreatic adenocarcinoma.淋巴细胞与单核细胞比值可预测胰腺腺癌的死亡率。
World J Gastrointest Pharmacol Ther. 2017 Feb 6;8(1):60-66. doi: 10.4292/wjgpt.v8.i1.60.
5
Preoperative Platelet-to-Albumin Ratio Predicts Prognosis of Patients with Pancreatic Ductal Adenocarcinoma After Pancreatic Resection.术前血小板与白蛋白比值可预测胰腺导管腺癌患者胰腺切除术后的预后。
Anticancer Res. 2017 Feb;37(2):787-793. doi: 10.21873/anticanres.11378.
6
Prognostic Value of the CRP/Alb Ratio, a Novel Inflammation-Based Score in Pancreatic Cancer.CRP/白蛋白比值作为一种基于炎症的新型评分在胰腺癌中的预后价值
Ann Surg Oncol. 2017 Feb;24(2):561-568. doi: 10.1245/s10434-016-5579-3. Epub 2016 Sep 20.
7
Prognostic value of inflammation-based markers in patients with pancreatic cancer administered gemcitabine and erlotinib.基于炎症的标志物在接受吉西他滨和厄洛替尼治疗的胰腺癌患者中的预后价值
World J Gastrointest Oncol. 2016 Jul 15;8(7):555-62. doi: 10.4251/wjgo.v8.i7.555.
8
Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin.中性粒细胞/淋巴细胞比值有助于筛选出能从奥沙利铂治疗中获益的转移性胰腺癌患者。
Cancer Biomark. 2016 Sep 26;17(3):335-345. doi: 10.3233/CBM-160645.
9
The C-reactive protein/albumin ratio predicts overall survival of patients with advanced pancreatic cancer.C反应蛋白与白蛋白比值可预测晚期胰腺癌患者的总生存期。
Tumour Biol. 2016 Sep;37(9):12525-12533. doi: 10.1007/s13277-016-5122-y. Epub 2016 Jun 25.
10
Prognostic role of platelet-lymphocyte ratio in colorectal cancer: A systematic review and meta-analysis.血小板-淋巴细胞比值在结直肠癌中的预后作用：一项系统评价和荟萃分析。
Medicine (Baltimore). 2016 Jun;95(24):e3837. doi: 10.1097/MD.0000000000003837.